- Home
- GHI vs LXEO Comparison
GHI vs LXEO Comparison
Compare GHI & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- LXEO
- Stock Information
- Founded
- GHI 1998
- LXEO 2017
- Country
- GHI United States
- LXEO United States
- Employees
- GHI N/A
- LXEO N/A
- Industry
- GHI Finance: Consumer Services
- LXEO
- Sector
- GHI Finance
- LXEO
- Exchange
- GHI Nasdaq
- LXEO Nasdaq
- Market Cap
- GHI 269.5M
- LXEO 257.0M
- IPO Year
- GHI N/A
- LXEO 2023
- Fundamental
- Price
- GHI $10.86
- LXEO $4.78
- Analyst Decision
- GHI Strong Buy
- LXEO Strong Buy
- Analyst Count
- GHI 4
- LXEO 7
- Target Price
- GHI $14.88
- LXEO $15.29
- AVG Volume (30 Days)
- GHI 63.7K
- LXEO 382.9K
- Earning Date
- GHI 08-07-2025
- LXEO 08-14-2025
- Dividend Yield
- GHI 13.67%
- LXEO N/A
- EPS Growth
- GHI N/A
- LXEO N/A
- EPS
- GHI N/A
- LXEO N/A
- Revenue
- GHI $27,326,828.00
- LXEO N/A
- Revenue This Year
- GHI $228.92
- LXEO N/A
- Revenue Next Year
- GHI $4.27
- LXEO N/A
- P/E Ratio
- GHI N/A
- LXEO N/A
- Revenue Growth
- GHI N/A
- LXEO N/A
- 52 Week Low
- GHI $10.12
- LXEO $1.45
- 52 Week High
- GHI $14.51
- LXEO $12.76
- Technical
- Relative Strength Index (RSI)
- GHI 49.88
- LXEO 57.39
- Support Level
- GHI $10.45
- LXEO $4.33
- Resistance Level
- GHI $11.12
- LXEO $5.05
- Average True Range (ATR)
- GHI 0.28
- LXEO 0.34
- MACD
- GHI 0.06
- LXEO 0.00
- Stochastic Oscillator
- GHI 71.51
- LXEO 62.66
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.